1. Home
  2. AER vs GMAB Comparison

AER vs GMAB Comparison

Compare AER & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AerCap Holdings N.V.

AER

AerCap Holdings N.V.

HOLD

Current Price

$135.14

Market Cap

22.9B

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$26.50

Market Cap

19.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AER
GMAB
Founded
1995
1999
Country
Ireland
Denmark
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.9B
19.1B
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
AER
GMAB
Price
$135.14
$26.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
7
Target Price
$150.29
$40.93
AVG Volume (30 Days)
1.4M
1.7M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
1.20%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$17.80
Revenue Next Year
$1.53
$14.86
P/E Ratio
$7.27
$1.90
Revenue Growth
N/A
N/A
52 Week Low
$85.57
$17.24
52 Week High
$154.94
$35.43

Technical Indicators

Market Signals
Indicator
AER
GMAB
Relative Strength Index (RSI) 37.61 33.14
Support Level $129.85 $20.83
Resistance Level $138.34 $33.75
Average True Range (ATR) 4.30 0.61
MACD -1.63 -0.10
Stochastic Oscillator 14.96 11.59

Price Performance

Historical Comparison
AER
GMAB

About AER AerCap Holdings N.V.

AerCap Holdings NV is an aircraft leasing company. Its activities include leasing, financing, sales, and management of commercial aircraft and engines. It also provides aircraft asset management and corporate services to securitization vehicles, joint ventures, and other third parties. It has one business segment: leasing, financing, sales, and management of commercial flight equipment (Commercial Flight Equipment Segment). Through its subsidiary, the group also provides engine leasing, certified aircraft engines, airframes, and engine parts. Its geographical segments include China, the United States, and Other countries.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: